Welcome to our dedicated page for IDEAYA Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on IDEAYA Biosciences stock.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is an innovative biotechnology firm concentrated on oncology. Established in 2015 and headquartered in South San Francisco and La Jolla, California, the company is dedicated to the discovery and development of precision medicine therapies for genetically defined patient groups. Their focus areas include synthetic lethality and immuno-oncology, targeting DNA damage repair mechanisms and the tumor microenvironment, respectively.
IDEAYA's pioneering approach leverages molecular diagnostics to identify and develop targeted therapeutics. The company's leading product candidate, IDE196, is a potent inhibitor of protein kinase C (PKC), aimed at treating cancers with GNAQ or GNA11 mutations. In addition, IDEAYA is advancing several clinical programs, such as the darovasertib program, which is currently in Phase 2 trials for uveal melanoma (UM) and has shown promising results in tumor shrinkage and eye preservation.
In synthetic lethality, IDEAYA's IDE397 targets methionine adenosyltransferase 2 alpha (MAT2A) in solid tumors with MTAP deletion, a condition prevalent in 15% of solid tumors. The IDE397 program includes both monotherapy and combination trials with other investigational drugs.
Financially, IDEAYA is robust with cash reserves exceeding $941.4 million as of Q1 2024, ensuring operational funding through 2028. Key investors include 5AM Ventures, Canaan Partners, and Celgene. The company has formed strategic collaborations with major pharmaceutical players like Pfizer, Amgen, Gilead Sciences, GSK, and Merck to amplify its research and clinical capabilities.
IDEAYA's scientific advisory board is composed of esteemed researchers, including a Nobel laureate and members of the National Academy of Sciences, underscoring the company's commitment to groundbreaking research.
Recent developments are promising: IDEAYA reported favorable Phase 2 trial results for IDE196 in UM, with significant tumor reduction and eye preservation rates. Additionally, a collaboration with Merck for the IDE161 program aims to tackle endometrial cancer using advanced immunotherapy combinations.
For more detailed updates and financial information, visit IDEAYA's Investor Relations page.
IDEAYA Biosciences (Nasdaq: IDYA) plans to offer and sell up to $80 million in common stock through an underwritten public offering, with an additional $12 million option for underwriters. Proceeds will support clinical development of its MAT2A inhibitor, ongoing research into poly (ADP-ribose) glycohydrolase targets, and further studies on darovasertib for treating metastatic uveal melanoma. The offering is pending market conditions and will be conducted under a shelf registration statement.
IDEAYA Biosciences (Nasdaq:IDYA) announced updates on its Phase 1 clinical trial for IDE397 and the initiation of a Phase 2 trial for darovasertib combination therapies in metastatic uveal melanoma. The early results for IDE397 show a significant reduction in plasma S-adenosyl methionine (SAM), suggesting effective target engagement. The company is expanding its clinical sites and has reported no serious drug-related adverse events. There are also promising early responses in darovasertib trials, including tumor reductions of up to 56.5%.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced its participation in the 2021 Jefferies Virtual Healthcare Conference on June 3, 2021, at 1:00 pm ET. The conference will feature a fireside chat with Maury Raycroft. A live audio webcast will be available on IDEAYA's website, with a replay accessible for 30 days following the event. IDEAYA focuses on synthetic lethality and precision medicine for oncology, integrating biomarker identification with drug discovery to enhance targeted therapeutics.
IDEAYA Biosciences (Nasdaq:IDYA) reported a business update and financial results for Q1 2021, highlighting development in its clinical trials, especially for IDE397, a MAT2A inhibitor targeting MTAP deletion tumors. The company announced a net loss of $9.0 million compared to $5.1 million in the previous quarter, with cash reserves amounting to $310.4 million. Collaboration revenue decreased to $7.2 million from $10.6 million. IDEAYA also expects to achieve multiple preclinical and clinical milestones across its targeted synthetic lethality programs in 2021 and beyond.
IDEAYA Biosciences (NASDAQ: IDYA) announced the dose expansion of its Phase 1/2 study on the darovasertib and crizotinib combination therapy for metastatic uveal melanoma (MUM). Encouraging early results indicate tumor reduction in two evaluable patients, including a notable 54% reduction in one patient. Despite drug-related adverse events such as syncope and hypotension, the combination therapy shows promise. Further patient enrollment continues as IDEAYA aims to explore additional doses, building on preliminary data and preclinical findings presented at AACR 2021.
IDEAYA Biosciences (NASDAQ: IDYA) announced its participation in the upcoming 2021 JP Morgan Conference Call Series. The fireside chat with analyst Anupam Rama will take place on May 10, 2021, at 11:00 am ET. A live audio webcast will be accessible on the IDEAYA website's Investor Calendar section, with a replay available for 30 days after the event. IDEAYA focuses on precision medicine oncology, particularly through synthetic lethality, aiming to develop targeted therapeutics based on molecular diagnostics.
IDEAYA Biosciences (NASDAQ: IDYA) announced its inaugural Synthetic Lethality Investor Day scheduled for April 20, 2021, from 1:00 pm to 3:00 pm ET. The virtual event will feature presentations from key opinion leaders and scientists from IDEAYA and GlaxoSmithKline (GSK), focusing on synthetic lethality in precision medicine. Topics include IDE397 targeting MAT2A in MTAP-deleted tumors and innovative cancer treatment strategies. Registration details are available on IDEAYA's website.
IDEAYA Biosciences (NASDAQ: IDYA) announced promising results from its ongoing Phase 1/2 trial of darovasertib (IDE196) for treating solid tumors, including Metastatic Uveal Melanoma (MUM). Key findings include a 57% one-year overall survival rate in heavily pre-treated MUM patients, compared to a historical rate of 37%. Additionally, 61% of MUM patients showed tumor reduction. The combination therapy with binimetinib also yielded early results, with 22% of MUM patients showing partial responses. The company continues its clinical development focus and will host an investor webcast for further insights.
IDEAYA Biosciences (NASDAQ: IDYA) announced an upcoming webcast on April 16, 2021, to discuss clinical data from its Phase 1/2 trial evaluating darovasertib (IDE196) as monotherapy and in combination with binimetinib for treating metastatic uveal melanoma. The company will host an Investor Day featuring leading clinical investigators. Additionally, the International Nonproprietary Name for IDE196 has been confirmed as darovasertib by WHO. The press release cautions investors about risks in drug development and the potential impacts of COVID-19 on business operations.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) has announced the dosing of the first patient in its Phase 1 clinical trial of IDE397, a methionine adenosyltransferase 2a (MAT2A) inhibitor, targeting patients with methylthioadenosine phosphorylase (MTAP) deletion, which occurs in about 15% of solid tumors. IDE397 has shown promising anti-tumor activity across various solid tumor types, including non-small cell lung cancer and gastric cancer. The trial's progress involves activating multiple clinical sites in the U.S. and using Next Generation Sequencing for patient identification.
FAQ
What is the current stock price of IDEAYA Biosciences (IDYA)?
What is the market cap of IDEAYA Biosciences (IDYA)?
What is IDEAYA Biosciences, Inc.?
What is the primary focus of IDEAYA's research?
What is IDEAYA's product pipeline?
Who are IDEAYA's key investors?
Where is IDEAYA Biosciences located?
What recent collaborations has IDEAYA announced?
What significant achievements has IDEAYA made recently?
What is IDEAYA's financial outlook?
Who comprises IDEAYA's scientific advisory board?
How can I stay updated on IDEAYA Biosciences?
